Compare Wendys Co (WEN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wendys Co vs Zimmer Biomet Holdings Inc — how do they compare? Wendys Co trades at $6.23 (market cap $1.19B), while Zimmer Biomet Holdings Inc trades at $89.49 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 14.2× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold Wendys Co for 77 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| WEN | ZBH | |
|---|---|---|
Market Cap | $1.19B | $16.95B |
Volume | 5,622,905 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.33 | $103.98 |
52-Week Low | $6.10 | $79.58 |
Typical Hold Time | 77 Days | 89 Days |
Enterprise Value | $4.92B | $24.02B |
Dividend Yield | 4.49% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wendy's (WEN) trades at $6.16, down 71% over five years, with a bearish technical signal and recent price near multi-year lows. The company faces declining same-store sales, a major franchisee bankruptcy (Meritage Hospitality, September 2026), and net income margin compression from 7.58% in 2025 to 5.72% in 2026. Valuation appears low with a P/E of 9.45 and P/S of 0.54, but high debt and operational challenges weigh on sentiment. Recent earnings beats provide some positive momentum, but competitive pressures persist.
The outlook remains cautious due to franchisee instability and sales declines. Investment opportunity lies in potential turnaround under new CEO Bob Wright and cheap valuation, but risks include further store closures, debt burden, and intense burger chain competition. Analyst consensus is mixed with a $7.58 price target, but 65% hold ratings reflect uncertainty.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
